Monday AM ASX Ann..??, page-5

Love it. You're on the ball, Davie!

The data speaks for itself. 70% BORR with no Grade 3 or higher adverse event for either Keytruda or Cavatak - very impressive. This ORR is superior than the results from the previous combination studies involving Keytruda, i.e. ~57/58% ORR (albeit with larger sample sizes). One caveat, however, I'd place on this is that all 7 of the responses were partial responses and not complete responses. We may just need more time for complete responses to occur.

Compare this with the T-VEC/Keytruda combo: the study achieved a confirmed DCR of 71.4% whereas CAPRA has reported 100%. The responses also seem to have general efficacy across all stages of advanced melanoma as per the line chart. There were complete responses observed in the T-VEC/Keytruda combo but this might have something to do with the larger sample (N=21) and larger amount of time lapsed. Confirmation of partial responses for both combo studies seem to occur around the same time.

These preliminary results are indeed excellent. On top of that, we still have theoretically another 18-20 (?) patients to reach the sample of 30 patients. I dare say that MITCI and CAPRA combined now should make it absolutely clear that Cavatak is not to be overlooked by the immunotherapy field. Would love to hear others' thoughts on whether these results are further pushing us towards a more commercially significant event. @Bella?